BioNexus Gene Lab Corp. Partners with ML Tech to Supercharge Ethereum Treasury Strategy

A Strategic Alliance for Digital Asset Growth

BioNexus Gene Lab Corp. (NASDAQ: BGLC), a forward-thinking technology company operating in the digital and healthcare sectors, has announced a groundbreaking partnership with ML Tech, a leading AI-powered digital asset wealth management platform. This collaboration aims to amplify BGLC's newly announced Ethereum treasury strategy, demonstrating the company's commitment to leveraging cutting-edge technology for financial growth.

Harnessing AI for Optimized Ethereum Returns

Headquartered in Miami, Florida, and regulated by the National Futures Association (NFA), ML Tech brings its institutional-grade trading infrastructure and advanced quantitative models to the table. This partnership will allow BGLC to tap into ML Tech's expertise in maximizing returns on Ethereum holdings while adhering to strict risk management protocols.

"Our quantitative trading expertise and non-custodial execution model will empower BGLC to optimize its Ethereum holdings while preserving full transparency and security," stated Leo Mindyuk, CEO and CIO of ML Tech, highlighting the value proposition of the partnership.

A Vision of Blockchain-Integrated Finance

This strategic move aligns perfectly with BGLC's broader vision of integrating blockchain technologies into its financial operations. By utilizing ML Tech's AI-driven platform, BGLC aims to enhance the efficiency and performance of its treasury, ensuring liquidity and control while growing its Ethereum reserves. This partnership also hints at the potential for exciting new financial structures within the open market.

Sam Tan, CEO of BioNexus Gene Lab Corp., emphasized the company's commitment to innovation, stating, "The decision to implement an Ethereum treasury strategy underscores our commitment to improving shareholder value through innovation in the digital, AI driven future." He further added, "Partnering with ML Tech enables us to leverage our assets with an expert in the field to enhance the efficiency and performance of our treasury operations."

Why ML Tech? A Focus on Institutional-Grade Strategies

BGLC's selection of ML Tech stems from the platform's proven ability to cater to institutional investors seeking low-correlation digital asset strategies. ML Tech's strong track record with delta-neutral and market-neutral strategies provides sophisticated quantitative solutions that navigate the intricacies of digital asset markets.

About the Companies

BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a technology company dedicated to pushing boundaries in the digital and healthcare landscapes. Focused on integrating cutting-edge technologies, BGLC strives to deliver sustainable growth and value to its shareholders. Learn more at https://www.bionexusgenelab.com/ethstrategy.

ML Tech is an institutional digital asset platform offering optimized blended portfolios and bespoke trading strategies. Investors gain access to real-time NAV, portfolio insights, and a suite of market-neutral and smart beta strategies through its marketplace. For more information, visit www.mltech.ai or contact allocators.ai.

Contact Information

For investor inquiries or media requests, please contact: IR.COM

Forward-Looking Statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. Actual results may differ materially from those projected due to various factors, including market conditions and regulatory developments. BioNexus Gene Lab Corp. assumes no obligation to update forward-looking statements, except as required by law.